GlobeNewswire
Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference
📊
AI Sentiment
Positive
7/10
- Home
- GNLX
GNLX
Genelux Corporation
as of 12-02-2025 4:00pm EST
$4.73
$0.17
-3.47%
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Chart Type:
Time Range:
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 202.4M | IPO Year: | 2023 |
| Target Price: | $19.75 | AVG Volume (30 days): | 313.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.99 - $8.54 | Next Earning Date: | 11-05-2025 |
| Revenue: | N/A | Revenue Growth: | -95.29% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered GNLX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 21 hours ago
AI Recommendation
hold
Model Accuracy: 77.31%
77.31%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Genelux Corporation News
GNLX Breaking Stock News: Dive into GNLX Ticker-Specific Updates for Smart Investing
Compare GNLX vs Leading Stocks
See how GNLX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GNLX Genelux Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.